To DTC or not to DTC?

Europe is debating drug marketing--and the pharma industry is loudly protesting that it is not asking for the right to pursue DTC advertising. "[S]uch mass media would not be appropriate means for the industry to communicate information on specific prescription medicines to European citizens," says Bayer CEO Arthur Higgins (photo), who's also president of the Euro trade group.

But what drugmakers want to be able to do is "raise awareness"--a.k.a. advertise--various diseases. Then, when patients look up info on their own, on the Internet, they'd get access to info about meds. It's unclear whether this means that companies could set up websites about, say, depression, that are simply gateways to drug-marketing sites. But a couple of patient advocacy groups are up in arms about the drug marketing proposals, so the debate's not over yet.

- see the story at PharmaTimes

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.